7 Oct 2021
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN-006 to Treat COVID-19
Author: admintech | Filed under: Press ReleaseDURHAM, N.C., Oct. 7, 2021 /PRNewswire/ — Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled “muco-trapping” antibody platform for treating acute respiratory infections, today announced that the first patient has been dosed in a Phase 1 safety and…